Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306631 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00306631 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT00306631, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This phase 2 study will determine the antitumor activity, based on the objective rate, of oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with advanced or metastatic breast carcinoma. The study will also evaluate the safety and response duration in patients, time to tumor progression, and overall survival in patients following MKC-1 therapy.
Interventions
- DRUG MKC-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306631
The ClinicalTrials.gov registry entry for NCT00306631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MKC-1 is the first listed.
NCT00306631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306631 about?
NCT00306631 is a clinical study titled "A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1". This phase 2 study will determine the antitumor activity, based on the objective rate, of oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with advanced or metastatic breast carcinoma. The study will also evaluate the safety and response duration in patients, t...
What is the current status of trial NCT00306631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00306631?
The interventions under investigation include: MKC-1 (DRUG).
Who is sponsoring clinical trial NCT00306631?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.